These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36032976)

  • 41. Persistence of an infectious form of SARS-CoV-2 post protease inhibitor treatment of permissive cells in vitro.
    Nair MS; Luck MI; Huang Y; Sabo Y; Ho DD
    J Infect Dis; 2024 Aug; ():. PubMed ID: 39132824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir.
    Hu Y; Lewandowski EM; Tan H; Zhang X; Morgan RT; Zhang X; Jacobs LMC; Butler SG; Gongora MV; Choy J; Deng X; Chen Y; Wang J
    bioRxiv; 2022 Sep; ():. PubMed ID: 36119652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations.
    Joyce RP; Hu VW; Wang J
    Med Chem Res; 2022; 31(10):1637-1646. PubMed ID: 36060104
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persistence of an infectious form of SARS-CoV-2 post protease inhibitor treatment of permissive cells in vitro.
    Nair MS; Luck MI; Huang Y; Sabo Y; Ho DD
    bioRxiv; 2023 Dec; ():. PubMed ID: 38187654
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ensitrelvir as a potential treatment for COVID-19.
    McCarthy MW
    Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
    Moghadasi SA; Biswas RG; Harki DA; Harris RS
    Res Sq; 2023 Mar; ():. PubMed ID: 36993515
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
    Moghadasi SA; Biswas RG; Harki DA; Harris RS
    bioRxiv; 2023 Feb; ():. PubMed ID: 36909573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04.
    Zhang L; Xie X; Luo H; Qian R; Yang Y; Yu H; Huang J; Shi PY; Hu Q
    Cell Discov; 2024 Apr; 10(1):40. PubMed ID: 38594245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    Res Sq; 2022 Aug; ():. PubMed ID: 36052369
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.
    Moghadasi SA; Heilmann E; Khalil AM; Nnabuife C; Kearns FL; Ye C; Moraes SN; Costacurta F; Esler MA; Aihara H; von Laer D; Martinez-Sobrido L; Palzkill T; Amaro RE; Harris RS
    bioRxiv; 2022 Dec; ():. PubMed ID: 35982678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A yeast-based system to study SARS-CoV-2 M
    Ou J; Lewandowski EM; Hu Y; Lipinski AA; Morgan RT; Jacobs LMC; Zhang X; Bikowitz MJ; Langlais P; Tan H; Wang J; Chen Y; Choy JS
    bioRxiv; 2022 Aug; ():. PubMed ID: 35982672
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection.
    Garneau WM; Jones-Beatty K; Ufua MO; Mostafa HH; Klein SL; Burd I; Gebo KA
    JAMA Netw Open; 2022 Nov; 5(11):e2244141. PubMed ID: 36445705
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen.
    Wang L; Yu Z; Wang S; Guo Z; Sun Q; Lai L
    Eur J Med Chem; 2022 Dec; 244():114803. PubMed ID: 36209629
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nirmatrelvir Plus Ritonavir: First Approval.
    Lamb YN
    Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
    Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
    ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prioritisation of Compounds for 3CL
    Jukič M; Škrlj B; Tomšič G; Pleško S; Podlipnik Č; Bren U
    Molecules; 2021 May; 26(10):. PubMed ID: 34070140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.